AX-2025-019784
Selank · 20 mg declared · Hubei Jianxiang Bioscience Co., Ltd. · lot HJ-2507-F3983
- Report ID
- AX-2025-019784
- Compound
- Selank
- Compound class
- Neuroactive and cognitive peptides
- Supplier
- HJ — Hubei Jianxiang Bioscience Co., Ltd.
- Batch / lot
- HJ-2507-F3983
- Declared label claim
- 20mg
- Laboratory
- Kestrel Bioanalytical
- Assay date
- 24 Aug 2025
- Submitted
- 19 Sep 2025
- Quarter
- 2025-Q3
- Submitter
- c.molnar
- Sample provenance
- Supplier-supplied
Results
Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 15 min gradient, 214 nm | 98.80 | % area | ≥ 99.0 | FAIL |
| Total impurities | RP-HPLC, sum of reported peaks | 1.20 | % area | ≤ 1.0 | FAIL |
| Largest single impurity | RP-HPLC — tuftsin fragment (−417 Da) | 0.53 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 751.4402 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, unit resolution (single quadrupole) | 751.4402 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | 0.0 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 84.75 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 83.73 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 23.21 | mg | 20 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 19.434 | mg | 20 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 97.2 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 9.17 | % | ≤ 12.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 5.53 | % | ≤ 10.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.55 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 6.10 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 15 min gradient | 3.44 | min | 3.47 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.34 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 64,667 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs diketopiperazine (−18 Da) | 1.62 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Selank — main peak | 3.44 | 4,801,986 | 98.80 | — |
| 2 | tuftsin fragment (−417 Da) | 3.13 | 25,760 | 0.53 | -417.235 |
| 3 | des-Thr (−101 Da) | 3.31 | 16,039 | 0.33 | -101.048 |
| 4 | diketopiperazine (−18 Da) | 3.53 | 8,749 | 0.18 | -18.011 |
| 5 | acetyl adduct (+42 Da) | 3.61 | 7,776 | 0.16 | +42.011 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 751.4402 Da, computed from C33H57N11O9. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 2+ | 376.7274 | 376.7274 | 0.0000 | 56.6 |
| 1+ | 752.4475 | 752.4475 | 0.0000 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 9.17 |
| Counter-ion (acetate) | ion chromatography | 5.53 |
| Residual solvent + inorganic residue | estimated | 0.55 |
| Total peptide content | by difference | 84.75 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.53 | 98.80 | divergence +0.56 pp vs batch median |
| Total impurities (% area) | 0.47 | 1.20 | |
| Largest single impurity (% area) | 0.21 | 0.53 | |
| Water (%) | not stated | 9.17 | |
| Counter-ion (%) | not stated | 5.53 | |
| Peptide content (%w/w) | not stated | 84.75 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Supplier-supplied
- Evidentiary weight
- Weaker evidence. Read with the caveat below.
- Chain of custody
- Supplier despatch → laboratory direct (courier, cold pack, 3 d) → assay. Submitter did not handle the vial.
- Assay date
- 24 Aug 2025
- Submitted to the index
- 19 Sep 2025
- Laboratory
- Kestrel Bioanalytical, Melbourne, Australia
- Method basis
- 15 min gradient · unit-resolution MS
- Verification status
- IDENTITY CONSISTENT
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot HJ-2507-F3983 n=2
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-019785 | HJ-2507-F3983 | Janoshik | 2025-Q3 | 99.14 | 8.98 | 94.9 | Supplier-supplied | 1 | MARGINAL |
Cross-sections
- All Selank records n=112
- All HJ records n=248
- All Kestrel records n=404
- All 2025-Q3 records n=819
- Selank by supplier
- Selank impurity profile
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042737 | GGPeps | GGPE-2603-J9708 | Janoshik | 2026-Q3 | 98.40 | 9.14 | 97.4 | Buyer-sourced | 0 | FAIL |
| AX-2026-042804 | GGPeps | GGPE-2602-G2056 | Janoshik | 2026-Q3 | 98.50 | 7.97 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-042803 | GGPeps | GGPE-2602-G2056 | Janoshik | 2026-Q3 | 98.48 | 8.01 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-042802 | GGPeps | GGPE-2602-G2056 | Janoshik | 2026-Q3 | 98.74 | 7.09 | 96.0 | Supplier-supplied | 0 | FAIL |
| AX-2026-042796 | GGPeps | GGPE-2602-G2056 | Janoshik | 2026-Q3 | 98.26 | 7.56 | 97.5 | Buyer-sourced | 0 | FAIL |
| AX-2026-042797 | GGPeps | GGPE-2602-G2056 | Medutest | 2026-Q3 | 98.46 | 7.92 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-042743 | GGPeps | GGPE-2603-J9708 | Medutest | 2026-Q3 | 99.59 | 9.37 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042799 | GGPeps | GGPE-2602-G2056 | Nordanalyt | 2026-Q3 | 98.77 | 8.33 | — | Supplier-supplied | 0 | FAIL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042368 | Semax | HJ-2603-V4363 | Nordanalyt | 2026-Q3 | 99.17 | 7.26 | 106.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042347 | Semaglutide | HJ-2608-C3931 | VendorInvestigate | 2026-Q3 | 98.80 | 3.41 | 100.2 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042367 | Semax | HJ-2603-V4363 | Kestrel | 2026-Q3 | 99.10 | 6.78 | 93.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042348 | Semaglutide | HJ-2608-C3931 | Nordanalyt | 2026-Q3 | 99.52 | 4.19 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042290 | GHRP-6 | HJ-2603-R2258 | Janoshik | 2026-Q3 | 99.71 | 3.05 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042287 | GHRP-6 | HJ-2603-R2258 | VendorInvestigate | 2026-Q3 | 98.79 | 2.43 | 90.9 | Buyer-sourced | 2 | FAIL |
| AX-2026-042288 | GHRP-6 | HJ-2603-R2258 | Kestrel | 2026-Q3 | 99.93 | 2.82 | 92.8 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042346 | Semaglutide | HJ-2608-C3931 | VendorInvestigate | 2026-Q3 | 99.40 | 3.48 | — | Buyer-sourced | 1 | MARGINAL |